Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
| Image |  |
|---|---|
| Description | scientific article published on 14 November 2017 |
| Author/s |
author: Jozef Sufliarsky Lars Lindner Maria Debiec-Rychter Bernard Escudier Laurence Albiges Piotr Rutkowski Viktor Grünwald Patrick Schöffski |
| Publication date | November 14, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |